



3-2021

Effectiveness of Cidofovir in Treating Natalizumab-Associated Progressive Multifocal Leukoencephalopathy (PML)

Salman Mansoor

University of Calgary, Alberta, Canada

Follow this and additional works at: <https://ecommons.aku.edu/pjns>

 Part of the [Neurology Commons](#)

Recommended Citation

Mansoor, Salman (2021) "Effectiveness of Cidofovir in Treating Natalizumab-Associated Progressive Multifocal Leukoencephalopathy (PML)," *Pakistan Journal of Neurological Sciences (PJNS)*: Vol. 16 : Iss. 1 , Article 11.

Available at: <https://ecommons.aku.edu/pjns/vol16/iss1/11>

EFFECTIVENESS OF CIDOFOVIR IN TREATING NATALIZUMAB-ASSOCIATED PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)

Salman Mansoor¹

¹Stroke Fellow, Calgary Stroke Program, University of Calgary, Alberta, Canada

Corresponding to:

Date of submission: Date of revision: Date of acceptance:

Clinical Question:

Is Cidofovir treatment in Natalizumab-associated Progressive Multifocal Leukoencephalopathy effective in MS Patients?

Background:

Natalizumab (Nz) a monoclonal antibody has been in medicinal use for treatment of Relapsing Remitting Multiple Sclerosis (RRMS) since 2004. Progressive Multifocal Leukoencephalopathy (PML) is one of its serious risks which is a demyelinating disorder of brain associated with John Cunningham Virus (JCV). There have been 801 cases up till December 2018 which were reported with its use¹. Lack of prospective trials and retrospective studies due to small number of these cases there is no consensus on Nz-associated PML treatment. To date there is no cure for this condition and there is a debate on effectiveness of different modalities². Cidofovir an antiviral drug which is used in cytomegalovirus retinitis, Aciclovir-resistant HSV infections^{3, 4}. The antiviral properties of Cidofovir are attributed to its active metabolite Cidofovir diphosphate which inhibits viral replication by impeding viral DNA polymerases⁵. Cidofovir is effective in polyomavirus like BK-virus in kidney transplant recipients. JCV belongs to the same family of Polyomaviruses⁵. Cidofovir has been used in selected cases with PML in various immunosuppressed states, hematological malignancies, post-transplant and HIV for the treatment of PML. This CAT aims to look at the evidence for using Cidofovir in Nz-associated PML.

Search Terms:

Cidofovir, Natalizumab, PML

Search Strategy:

An online search including Pubmed and Cochrane library was conducted dated 12th April 2019 to look for available evidence with search terms as mentioned through below links.

<https://www.ncbi.nlm.nih.gov/pubmed/>

<https://www.cochranelibrary.com>

Search Outcome:

Search in Pubmed Central showed 71 studies and case reports with the search term

There were 14 studies and case reports which were studied in depth for this CAT 4 case reports which fulfilled the criteria were included 10 studies which partially encompassed the scope of this CAT were discussed in the references. (Appendix 1)

Search in the Cochrane library with the search terms showed 3 reviews and 120 controlled trials These reviews and controlled trials were beyond the scope of this study, so these were excluded. (Appendix 2)

Evidence Included in This CAT:

1. Pathologic Findings of Chronic PML-IRIS in a Patient with Prolonged PML Survival Following Natalizumab Treatment. Himedan M, Camelo-Piragua S, Mills EA, Gupta A, Aburashed R, Mao-Draayer Y. J Investig Med High Impact Case Rep. 2017 Sep 27;5(3):2324709617734248. doi: 10.1177/2324709617734248. eCollection 2017 Jul-Sep. (Case Report 1 in Table.1)
2. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. N Engl J Med. 2005 Jul 28;353(4):375-81. Epub 2005 Jun 9. (Case Report 3 in Table.1)
3. Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen. Hervás JV, Presas-Rodríguez S, Crespo-Cuevas AM, Canento T, Lozano-Sánchez M, Massuet-Vilamajó A, Ramo-Tello C. Neurodegener Dis Manag. 2015 Oct;5(5):399-402. doi: 10.2217/nmt.15.42. Epub 2015 Oct 30. (Case Report 4 in Table 1)
4. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Clifford DB, DeLuca A, Simpson DM, Arendt G, Giovannoni G, Nath A. The Lancet Neurology. 2010 Apr;9(4):438-46.

Table 1. Cidofovir use in associated Progressive Multifocal Leukoencephalopathy in MS

Reference	C	Condition	Presentation	Diagnosis	DMT's Used	Natalizumab Duration	Drug Regimen	Course	DMT's Restarted
1.Himedan M et al	49 M	RRMS	Left Arm,Leg, Face weakness and Unsteadiness	MRI Brain, JCV+ PCR in CSF	Interferon beta-1a, Mitoxant rone	3.5 Years	PLEX 5-Days, IVIG IV Methyl prednis olone, Cidofovir, Maravir oc, Mirtaze pine, Levetira cetam	Seizures, Immune Reconstitution Inflammatory Syndrome (IRIS) 7 weeks after PLEX – Also on Brain Biopsy 3.5 years after death	Interferon beta-1a after 6 months
2. Langer-Gould A et al	44 M	RRMS	Started with a suspicious MRI brain lesion followed by subtle personality changes followed by attention deficits, dysarthria, Left Hemiparesis, cognitive deficits, hemineglect, quadriparesis, and minimal alertness – IRIS developed in brain biopsy 3 months after Natalizumab was stopped	MRI Brain, JCV+ PCR, CSF, Brain biopsy	Interferon beta-1a	28 - months	IV Methyl Prednis olone, Cidofovir (5mg/kg) every 2 weeks, IVIG, Cytarabine	After Cidofovir initially the condition deteriorated later cytarabine was added neurological stabilization – pancytopenia ensued given erythropoietin and granulocyte colony-stimulating factor	Not mentioned

3. José Vicente Hervás-García et al	51 M	RRMS	Aphasia was the initial presenting feature with MRI evidence –	MRI Brain consistent with PML, Initially JCV PCR was negative	No previous DMT's	4 years was on 4 weekly which was changed to 6-weekly for 1 year	PLEX, Cidofovir, Mirtazapine, Mefloquine and IV steroids	In the following 2 months clinical and radiological worsening with 1 month after the diagnosis JCV PCR was +ive which rechecked was -ive at 3 months with improvements Clinically however no specifics given	Not mentioned
4. Clifford DB, DeLuca A, Simpson DM et al	45 F	RRMS	Homonymous hemianopsia	JCV-PCR +ive in CSF	Mitoxant rone, IFN	34 - Months	PLEX, Cidofovir	IRIS Developed at 7 weeks after initiating PML treatment with clinical worsening in cognition	Not Mentioned
5. Clifford DB, DeLuca A, Simpson DM et al	36 F	RRMS	Homonymous hemianopsia, decreased cognition	JCV-PCR +ive, MRI- showed GD-enhancing lesions	Glatiramer acetate, IFN	25- Months	PLEX, mefloquine, mirtazapine, cidofovir	IRIS Developed progression of symptoms	Not mentioned

Summary:

Natalizumab associated PML is one of the major side-effects in Multiple Sclerosis patients. The long-term outcomes vary in individual cases. Patients who develop the condition mainly have two strong associations, the JCV serology titer index and the duration of treatment. In search for answering the question if Cidofovir is effective treatment there is ancillary evidence from case reports supporting it in Natalizumab associated PML. Owing to the small number of these cases a randomized controlled trial encompassing different drugs and including outcome variables is not possible.

An interesting review on PML recommended conflicting evidence on effectiveness of Cidofovir in PML⁶. Studies and reports which suggested ineffectiveness of cidofovir were both conducted in AIDS-associated PML⁷⁻⁹. Three interesting non-AIDS related case reports supported Cidofovir with positive outcomes¹⁰⁻¹². The results of these outcomes in Natalizumab associated PML can they be generalized, remains ambiguous.

In a case series of 28 Natalizumab associated patients 2 of the patients received Cidofovir their treatment outcomes at 3-months showed stabilization¹³. Adjunctive therapy including plasma exchange, and Cidofovir in one patient was used. The second patient was treated with Cidofovir, Mirtazepine, Mefloquine and Plasma Exchange¹³.

In this CAT an analysis of 5 cases were included of Natalizumab associated PML which were treated with Cidofovir in different treatment combinations. Owing to small number of cases which encompassed this CAT it is difficult to come to any specific conclusion. There was clinical stabilization in 4 cases that was achieved, and 1 case had an initial deterioration. In all the 5 cases there was a serological remission at the end. One strong reason for such an observation could be a publication bias. Multi-drug regimen specific to each case was used including Mirtazepine, Mefloquine, Cidofovir, Cytarabine, and plasma exchange. These are further individually classified in Table.1.

Clinical Bottom Line:

It's very difficult to generalize the results of this CAT due to the small number of cases which are associated with Natalizumab treated with Cidofovir and an unavailability of Randomized controlled trials.

However, the results which did encompass a small number of patients were suggestive of serological remission, and clinical stabilization with Cidofovir and the adjunctive therapy.

References:

1. TYSABRI_ (natalizumab): PML Incidence in Patients Receiving TYSABRI. Biogen Data on File. <https://medinfo.biogen.com/> 2018
2. Clifford DB. Progressive multifocal leukoencephalopathy therapy. *J Neurovirol.* 2015 Dec;21(6):632-6.
3. "Vistide (cidofovir) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 4 February 2014.
4. Chilukuri S, Rosen T. Management of acyclovir-resistant herpes simplex virus. *Dermatologic Clinics.* 2003 Apr;21(2):311-20.
5. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-01028-3>
6. Aksamit AJ. Progressive multifocal leukoencephalopathy. *Curr Treat Options Neurol.* 2008 May;10(3):178-85.
7. De Luca A, Ammassari A, Pezzotti P, Cinque P, Gasnault J, Berenguer J, et al. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. *AIDS.* 2008 Sep 12;22(14):1759-67.
8. Marra CM, Rajicic N, Barker DE, Cohen BA, Clifford D, Donovan Post MJ, et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. *AIDS.* 2002 Sep 6;16(13):1791-7.
9. Houston S, Roberts N, Mashinter L. Failure of cidofovir therapy in progressive multifocal leukoencephalopathy unrelated to human immunodeficiency virus. *Clin Infect Dis.* 2001 Jan;32(1):150-2.
10. Razonable RR, Aksamit AJ, Wright AJ, Wilson JW. Cidofovir treatment of progressive multifocal leukoencephalopathy in a patient receiving highly active antiretroviral therapy. *Mayo Clin Proc.* 2001 Nov;76(11):1171-5.
11. Viillard JF, Lazaro E, Ellie E, Eimer S, Camou F, Caubet O, et al. Improvement of progressive multifocal leukoencephalopathy after cidofovir therapy in a patient with a destructive polyarthritis. *Infection.* 2007 Feb;35(1):33-6.
12. Park JH, Ryoo S, Noh HJ, Seo JM, Kang HH, Shin JS, et al. Dual therapy with cidofovir and mirtazapine for progressive multifocal leukoencephalopathy in a sarcoidosis patient. *Case Rep Neurol.* 2011 Sep;3(3):258-62.
13. Clifford DB, De Luca A, DeLuca A, Simpson DM, Arendt G, Giovannoni G, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. *Lancet Neurol.* 2010 Apr;9(4):438-46.

Conflict of interest: Author declares no conflict of interest.

Funding disclosure: Nil

Author's contribution: